CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
N-acetylcysteine +1 moredrug
Likely dose
N-acetylcysteine 240mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00655928
NCT00655928Phase 2Completed
CompareCT.gov

Modulation of Lung Injury Complicating Lung Resection

Imperial College London·interventional·Posted Apr 10, 2008·Updated Feb 5, 2020

In Brief

A Phase 2 clinical trial evaluating N-acetylcysteine and 0.9% saline for Acute Lung Injury. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether N-acetylcysteine given intravenously 1 day pre-operatively is effective in preventing inflammation in the lungs, as measured by tests on blood, breath and lung specimens, in patients undergoing surgery to remove a portion of lung.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lung Injury
CountriesUnited Kingdom
CollaboratorsRoyal College of Physicians, Royal Brompton & Harefield NHS Foundation Trust

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 10, 2008
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.2 years ago

Interventions

N-acetylcysteinedrug

N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively

0.9% salinedrug

0.9% saline 1 litre intravenous over 12 hours pre-operatively